ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?
unknown
📅 Published: 2026-03-19 12:37
📰 Source: Yahoo
📝 Words: 20
📝 Article Content
AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
📄 Summary
AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-20 04:09:38
Updated At:
2026-03-20 04:09:38
Scraping Job ID:
N/A
Stock Mentions:
V - Visa Inc.
Relevance: N/A
ABBV - AbbVie Inc.
Relevance: N/A